Shankar Siva: SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma
Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, shared a post on X about recent paper by Constanza Vargas et al.:
“New trial analysis from FASTRACKII: in kidney cancer, SABR increased efficacy and decreased cost than radiofrequency or cryoablation.
- QALYs: SABR 4.00 vs RFA/CA 3.07
- Cost: SABR A$31,053 vs RFA A$35,001 vs CA A$36,356
- Net savings ~$4K/patient.”
Title: SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial
Authors: Constanza Vargas, Joe Carrello, Mathias Bressel, Mark Sidhom, Charles Lin, Ben Vanneste, Daniel Moon, Sree Appu, Anand Swaminath, Jeremy Ruben, David Pryor, Braden Higgs, Ryan Davey, Nicholas Hardcastle, Rebecca Montgomery, Shankar Siva, and Richard De Abreu Lourenço
Read The Full Article at International Journal of Radiation Oncology*Biology*Physics.
More posts featuring Shankar Siva on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023